{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T10:59:02Z","timestamp":1793271542600,"version":"4.5.0"},"reference-count":128,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1038\/s41584-025-01229-6","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T12:55:23Z","timestamp":1741784123000},"page":"237-248","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Delineating inflammatory from non-inflammatory mechanisms for therapy optimization in psoriatic arthritis"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0573-464X","authenticated-orcid":false,"given":"Alen","family":"Zabotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8792-4449","authenticated-orcid":false,"given":"Sibel Zehra","family":"Aydin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0075-5895","authenticated-orcid":false,"given":"Paula","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Di Matteo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7715-8226","authenticated-orcid":false,"given":"Dennis","family":"McGonagle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"key":"1229_CR1","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/ard-2024-225531","volume":"83","author":"L Gossec","year":"2024","unstructured":"Gossec, L. et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann. Rheum. Dis. 83, 706\u2013719 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"1229_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann. Rheum. Dis. 82, 3\u201318 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"1229_CR3","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1136\/ard-2023-225087","volume":"83","author":"H Marzo-Ortega","year":"2024","unstructured":"Marzo-Ortega, H. et al. Time to address the challenge of difficult to treat psoriatic arthritis: results from an international survey. Ann. Rheum. Dis. 83, 403\u2013404 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"1229_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","volume":"80","author":"G Nagy","year":"2021","unstructured":"Nagy, G. et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann. Rheum. Dis. 80, 31\u201335 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"1229_CR5","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s40744-022-00461-w","volume":"9","author":"FM Perrotta","year":"2022","unstructured":"Perrotta, F. M., Scriffignano, S., Ciccia, F. & Lubrano, E. Clinical characteristics of potential \u2018Difficult-to-treat\u2019 patients with psoriatic arthritis: a retrospective analysis of a longitudinal cohort. Rheumatol. Ther. 9, 1193\u20131201 (2022).","journal-title":"Rheumatol. Ther."},{"key":"1229_CR6","doi-asserted-by":"publisher","unstructured":"Paudel, M. L. et al. Prevalence and characteristics of adults with difficult-to-treat rheumatoid arthritis in a large patient registry. Rheumatology https:\/\/doi.org\/10.1093\/rheumatology\/keae318 (2024).","DOI":"10.1093\/rheumatology\/keae318"},{"key":"1229_CR7","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1136\/ard-2023-224916","volume":"83","author":"KL Winthrop","year":"2024","unstructured":"Winthrop, K. L. et al. Unmet need in rheumatology: reports from the advances in targeted therapies meeting, 2023. Ann. Rheum. Dis. 83, 409\u2013416 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"1229_CR8","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/art.42767","volume":"76","author":"P David","year":"2024","unstructured":"David, P. et al. Poly-refractory rheumatoid arthritis: an uncommon subset of difficult to treat disease with distinct inflammatory and noninflammatory phenotypes. Arthritis Rheumatol. 76, 510\u2013521 (2024).","journal-title":"Arthritis Rheumatol."},{"key":"1229_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003809","volume":"10","author":"S Singla","year":"2024","unstructured":"Singla, S., Ribeiro, A., Torgutalp, M., Mease, P. J. & Proft, F. Difficult-to-treat psoriatic arthritis (D2T PsA): a scoping literature review informing a GRAPPA research project. RMD Open. 10, e003809 (2024).","journal-title":"RMD Open."},{"key":"1229_CR10","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s40744-023-00574-w","volume":"10","author":"E Lubrano","year":"2023","unstructured":"Lubrano, E., Scriffignano, S. & Perrotta, F. M. Difficult to treat and refractory to treatment in psoriatic arthritis. Rheumatol. Ther. 10, 1119\u20131125 (2023).","journal-title":"Rheumatol. Ther."},{"key":"1229_CR11","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1136\/ard-2022-223650","volume":"82","author":"B Glintborg","year":"2023","unstructured":"Glintborg, B. et al. Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registries. Ann. Rheum. Dis. 82, 820\u2013828 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"1229_CR12","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1093\/rheumatology\/keaa030","volume":"59","author":"B Hag\u00e8ge","year":"2020","unstructured":"Hag\u00e8ge, B. et al. Remission and low disease activity in psoriatic arthritis publications: a systematic literature review with meta-analysis. Rheumatology 59, 1818\u20131825 (2020).","journal-title":"Rheumatology"},{"key":"1229_CR13","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3899\/jrheum.2023-0716","volume":"51","author":"DD Gladman","year":"2024","unstructured":"Gladman, D. D. et al. Residual disease activity in Canadian patients with psoriatic arthritis treated with advanced therapies: results from a multiregistry analysis (UNISON-PsA). J. Rheumatol. 51, 479\u2013487 (2024).","journal-title":"J. Rheumatol."},{"key":"1229_CR14","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40744-019-00171-w","volume":"6","author":"E Lubrano","year":"2019","unstructured":"Lubrano, E., Perrotta, F. M., Scriffignano, S., Coates, L. C. & Helliwell, P. Sustained very low disease activity and remission in psoriatic arthritis patients. Rheumatol. Ther. 6, 521\u2013528 (2019).","journal-title":"Rheumatol. Ther."},{"key":"1229_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001170","volume":"6","author":"E Lubrano","year":"2020","unstructured":"Lubrano, E. et al. Assessment of the Patient Acceptable Symptom State (PASS) in psoriatic arthritis: association with disease activity and quality of life indices. RMD Open. 6, e001170 (2020).","journal-title":"RMD Open."},{"key":"1229_CR16","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s40744-024-00698-7","volume":"11","author":"S S","year":"2024","unstructured":"S, S. et al. Psoriatic arthritis acceptable symptoms state: does sex make a difference? Rheumatol. Ther. 11, 1393\u20131402 (2024).","journal-title":"Rheumatol. Ther."},{"key":"1229_CR17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41584-020-00541-7","volume":"17","author":"MH Buch","year":"2021","unstructured":"Buch, M. H., Eyre, S. & McGonagle, D. Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis. Nat. Rev. Rheumatol. 17, 17\u201333 (2021).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1229_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22265-2","volume":"12","author":"A Eshaghi","year":"2021","unstructured":"Eshaghi, A. et al. Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data. Nat. Commun. 12, 2078 (2021).","journal-title":"Nat. Commun."},{"key":"1229_CR19","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/S1474-4422(22)00289-7","volume":"22","author":"T Kuhlmann","year":"2023","unstructured":"Kuhlmann, T. et al. Multiple sclerosis progression: time for a new mechanism-driven framework. Lancet Neurol. 22, 78\u201388 (2023).","journal-title":"Lancet Neurol."},{"key":"1229_CR20","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nrrheum.2017.188","volume":"13","author":"G Schett","year":"2017","unstructured":"Schett, G. et al. Enthesitis: from pathophysiology to treatment. Nat. Rev. Rheumatol. 13, 731\u2013741 (2017).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1229_CR21","doi-asserted-by":"publisher","first-page":"ii14","DOI":"10.1136\/ard.2004.032482","volume":"64","author":"DD Gladman","year":"2005","unstructured":"Gladman, D. D., Antoni, C., Mease, P., Clegg, D. O. & Nash, P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann. Rheum. Dis. 64, ii14\u2013741 (2005). ii14-17.","journal-title":"Ann. Rheum. Dis."},{"key":"1229_CR22","first-page":"668","volume":"35","author":"URC Lindqvist","year":"2008","unstructured":"Lindqvist, U. R. C. et al. The Swedish early psoriatic arthritis register \u2014 2-year followup: a comparison with early rheumatoid arthritis. J. Rheumatol. 35, 668\u2013673 (2008).","journal-title":"J. Rheumatol."},{"key":"1229_CR23","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1002\/art.22758","volume":"56","author":"D McGonagle","year":"2007","unstructured":"McGonagle, D., Lories, R. J. U., Tan, A. L. & Benjamin, M. The concept of a \u2018synovio-entheseal complex\u2019 and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond. Arthritis Rheum. 56, 2482\u20132491 (2007).","journal-title":"Arthritis Rheum."},{"key":"1229_CR24","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/BOR.0000000000000768","volume":"33","author":"SZ Aydin","year":"2021","unstructured":"Aydin, S. Z., Bridgewood, C., Zabotti, A., Girolimetto, N. & McGonagle, D. The transition from enthesis physiological responses in health to aberrant responses that underpin spondyloarthritis mechanisms. Curr. Opin. Rheumatol. 33, 64\u201373 (2021).","journal-title":"Curr. Opin. Rheumatol."},{"key":"1229_CR25","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1159\/000341536","volume":"225","author":"DG McGonagle","year":"2012","unstructured":"McGonagle, D. G., Helliwell, P. & Veale, D. Enthesitis in psoriatic disease. Dermatol. Basel Switz. 225, 100\u2013109 (2012).","journal-title":"Dermatol. Basel Switz."},{"key":"1229_CR26","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/art.42971","volume":"77","author":"A Di Matteo","year":"2024","unstructured":"Di Matteo, A. et al. Relationship Between ultrasound and physical examination in the assessment of enthesitis in patients with spondyloarthritis: results from the DEUS multicenter study. Arthritis Rheumatol. 77, 22\u201333 (2024).","journal-title":"Arthritis Rheumatol."},{"key":"1229_CR27","doi-asserted-by":"publisher","first-page":"968","DOI":"10.3899\/jrheum.190540","volume":"47","author":"S Bakirci","year":"2020","unstructured":"Bakirci, S. et al. Entheseal changes in response to age, body mass index, and physical activity: an ultrasound study in healthy people. J. Rheumatol. 47, 968\u2013972 (2020).","journal-title":"J. Rheumatol."},{"key":"1229_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000486","volume":"3","author":"B Michelsen","year":"2017","unstructured":"Michelsen, B. et al. Achilles enthesitis defined by ultrasound is not associated with clinical enthesitis in patients with psoriatic arthritis. RMD Open. 3, e000486 (2017).","journal-title":"RMD Open."},{"key":"1229_CR29","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1136\/ard-2022-223365","volume":"82","author":"A Kerschbaumer","year":"2023","unstructured":"Kerschbaumer, A. et al. Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann. Rheum. Dis. 82, 95\u2013106 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"1229_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000427","volume":"3","author":"L Terslev","year":"2017","unstructured":"Terslev, L. et al. Scoring ultrasound synovitis in rheumatoid arthritis: a EULAR-OMERACT ultrasound taskforce \u2014 part 2: reliability and application to multiple joints of a standardised consensus-based scoring system. RMD Open. 3, e000427 (2017).","journal-title":"RMD Open."},{"key":"1229_CR31","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.3899\/jrheum.100483","volume":"37","author":"SM Reddy","year":"2010","unstructured":"Reddy, S. M. et al. Comparative analysis of disease activity measures, use of biologic agents, body mass index, radiographic features, and bone density in psoriatic arthritis and rheumatoid arthritis patients followed in a large U.S. disease registry. J. Rheumatol. 37, 2566\u20132572 (2010).","journal-title":"J. Rheumatol."},{"key":"1229_CR32","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.jaad.2023.10.021","volume":"90","author":"JF Merola","year":"2024","unstructured":"Merola, J. F., Chakravarty, S. D., Choi, O., Chan, D. & Gottlieb, A. B. A clinical review of structural damage in psoriatic arthritis for dermatologists: from pathogenesis to ongoing controversies. J. Am. Acad. Dermatol. 90, 349\u2013357 (2024).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1229_CR33","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/art.42051","volume":"74","author":"S Honda","year":"2022","unstructured":"Honda, S. et al. Association of polygenic risk scores with radiographic progression in patients with rheumatoid arthritis. Arthritis Rheumatol. 74, 791\u2013800 (2022).","journal-title":"Arthritis Rheumatol."},{"key":"1229_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004080","volume":"10","author":"GH Koc","year":"2024","unstructured":"Koc, G. H. et al. Determinants of radiographic progression in early psoriatic arthritis: insights from a real-world cohort. RMD Open. 10, e004080 (2024).","journal-title":"RMD Open."},{"key":"1229_CR35","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.3899\/jrheum.180971","volume":"46","author":"D van der Heijde","year":"2019","unstructured":"van der Heijde, D. et al. Radiographic progression according to baseline C-reactive protein levels and other risk factors in psoriatic arthritis treated with tofacitinib or adalimumab. J. Rheumatol. 46, 1089\u20131096 (2019).","journal-title":"J. Rheumatol."},{"key":"1229_CR36","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor, W. et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 54, 2665\u20132673 (2006).","journal-title":"Arthritis Rheum."},{"key":"1229_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004314","volume":"10","author":"A Zabotti","year":"2024","unstructured":"Zabotti, A. et al. Risk of developing psoriatic arthritis in psoriasis cohorts with arthralgia: exploring the subclinical psoriatic arthritis stage. RMD Open. 10, e004314 (2024).","journal-title":"RMD Open."},{"key":"1229_CR38","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s13075-022-02944-1","volume":"24","author":"P Mease","year":"2022","unstructured":"Mease, P. et al. Quantification of pre-existing radiographic damage and its relationship with joint activity and long-term clinical outcomes with secukinumab therapy in patients with psoriatic arthritis. Arthritis Res. Ther. 24, 283 (2022).","journal-title":"Arthritis Res. Ther."},{"key":"1229_CR39","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1136\/annrheumdis-2021-220964","volume":"81","author":"S Dubash","year":"2022","unstructured":"Dubash, S. et al. Dactylitis is an indicator of a more severe phenotype independently associated with greater SJC, CRP, ultrasound synovitis and erosive damage in DMARD-naive early psoriatic arthritis. Ann. Rheum. Dis. 81, 490\u2013495 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"1229_CR40","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3899\/jrheum.190046","volume":"47","author":"N Girolimetto","year":"2020","unstructured":"Girolimetto, N. et al. Ultrasonographic evidence of predominance of acute extracapsular and chronic intrasynovial patterns in 100 cases of psoriatic hand dactylitis. J. Rheumatol. 47, 227\u2013233 (2020).","journal-title":"J. Rheumatol."},{"key":"1229_CR41","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates, L. C. et al. Group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat. Rev. Rheumatol. 18, 465\u2013479 (2022).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1229_CR42","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1093\/rheumatology\/keab784","volume":"61","author":"F Behrens","year":"2022","unstructured":"Behrens, F. et al. Efficacy and safety of secukinumab in patients with spondyloarthritis and enthesitis at the Achilles tendon: results from a phase 3b trial. Rheumatology 61, 2856\u20132866 (2022).","journal-title":"Rheumatology"},{"key":"1229_CR43","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13075-022-02797-8","volume":"24","author":"X Baraliakos","year":"2022","unstructured":"Baraliakos, X. et al. Magnetic resonance imaging characteristics in patients with spondyloarthritis and clinical diagnosis of heel enthesitis: post hoc analysis from the phase 3 ACHILLES trial. Arthritis Res. Ther. 24, 111 (2022).","journal-title":"Arthritis Res. Ther."},{"key":"1229_CR44","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1093\/rheumatology\/kex179","volume":"56","author":"A Zabotti","year":"2017","unstructured":"Zabotti, A. et al. Musculoskeletal ultrasonography for psoriatic arthritis and psoriasis patients: a systematic literature review. Rheumatology 56, 1518\u20131532 (2017).","journal-title":"Rheumatology"},{"key":"1229_CR45","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1136\/ard-2023-225278","volume":"83","author":"E Naredo","year":"2024","unstructured":"Naredo, E. et al. Validation and incorporation of digital entheses into a preliminary GLobal OMERACT Ultrasound DActylitis Score (GLOUDAS) in psoriatic arthritis. Ann. Rheum. Dis. 83, 1060\u20131071 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"1229_CR46","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1136\/annrheumdis-2020-217191","volume":"79","author":"A Zabotti","year":"2020","unstructured":"Zabotti, A. et al. Novel and reliable DACTylitis glObal Sonographic (DACTOS) score in psoriatic arthritis. Ann. Rheum. Dis. 79, 1037\u20131043 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"1229_CR47","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1136\/ard-2023-225443","volume":"83","author":"A Di Matteo","year":"2024","unstructured":"Di Matteo, A. et al. Power Doppler signal at the enthesis and bone erosions are the most discriminative OMERACT ultrasound lesions for SpA: results from the DEUS (Defining Enthesitis on Ultrasound in Spondyloarthritis) multicentre study. Ann. Rheum. Dis. 83, 847\u2013857 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"1229_CR48","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1136\/ard-2022-222787","volume":"82","author":"I Gessl","year":"2023","unstructured":"Gessl, I. et al. Tenderness and radiographic progression in rheumatoid arthritis and psoriatic arthritis. Ann. Rheum. Dis. 82, 344\u2013350 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"1229_CR49","first-page":"626","volume":"42","author":"G Smerilli","year":"2024","unstructured":"Smerilli, G. et al. Double target\u2019 ultrasound monitoring of biologic therapy in psoriatic arthritis. Clin. Exp. Rheumatol. 42, 626\u2013632 (2024).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1229_CR50","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/s41584-022-00776-6","volume":"18","author":"G Schett","year":"2022","unstructured":"Schett, G. et al. Psoriatic arthritis from a mechanistic perspective. Nat. Rev. Rheumatol. 18, 311\u2013325 (2022).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1229_CR51","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.3390\/jcm9103262","volume":"9","author":"L Savage","year":"2020","unstructured":"Savage, L. et al. Defining pre-clinical psoriatic arthritis in an integrated dermato-rheumatology environment. J. Clin. Med. 9, 3262 (2020).","journal-title":"J. Clin. Med."},{"key":"1229_CR52","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1002\/art.38050","volume":"65","author":"C Castillo-Gallego","year":"2013","unstructured":"Castillo-Gallego, C., Aydin, S. Z., Emery, P., McGonagle, D. G. & Marzo-Ortega, H. Magnetic resonance imaging assessment of axial psoriatic arthritis: extent of disease relates to HLA-B27. Arthritis Rheum. 65, 2274\u20132278 (2013).","journal-title":"Arthritis Rheum."},{"key":"1229_CR53","doi-asserted-by":"publisher","first-page":"4103","DOI":"10.1093\/rheumatology\/keaa885","volume":"60","author":"N Girolimetto","year":"2021","unstructured":"Girolimetto, N. et al. Sensitivity to change and clinical correlations of the novel DACtylitis glObal Sonographic (DACTOS) score in psoriatic arthritis. Rheumatology 60, 4103\u20134111 (2021).","journal-title":"Rheumatology"},{"key":"1229_CR54","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1136\/annrheumdis-2018-213025","volume":"77","author":"A Zabotti","year":"2018","unstructured":"Zabotti, A. et al. Ultrasonography in psoriatic arthritis: which sites should we scan? Ann. Rheum. Dis. 77, 1537\u20131538 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"1229_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/rheumatology\/kead288","volume":"63","author":"SZ Aydin","year":"2024","unstructured":"Aydin, S. Z. & Deodhar, A. Are all entheses the same? Rheumatology 63, 1\u20132 (2024).","journal-title":"Rheumatology"},{"key":"1229_CR56","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3389\/fmed.2020.00141","volume":"7","author":"G Sakellariou","year":"2020","unstructured":"Sakellariou, G. et al. Differential diagnosis of inflammatory arthropathies by musculoskeletal ultrasonography: a systematic literature review. Front. Med. 7, 141 (2020).","journal-title":"Front. Med."},{"key":"1229_CR57","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1136\/ard-2023-225247","volume":"83","author":"I Gessl","year":"2024","unstructured":"Gessl, I. et al. Systematic literature review to inform the EULAR recommendations for the use of imaging in crystal-induced arthropathies in clinical practice. Ann. Rheum. Dis. 83, 1208\u20131224 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"1229_CR58","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1093\/rheumatology\/kex079","volume":"57","author":"A Marchesoni","year":"2018","unstructured":"Marchesoni, A. et al. The problem in differentiation between psoriatic-related polyenthesitis and fibromyalgia. Rheumatology 57, 32\u201340 (2018).","journal-title":"Rheumatology"},{"key":"1229_CR59","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3899\/jrheum.120238","volume":"89","author":"A Marchesoni","year":"2012","unstructured":"Marchesoni, A., De Lucia, O., Rotunno, L., De Marco, G. & Manara, M. Entheseal power Doppler ultrasonography: a comparison of psoriatic arthritis and fibromyalgia. J. Rheumatol. Suppl. 89, 29\u201331 (2012).","journal-title":"J. Rheumatol. Suppl."},{"key":"1229_CR60","first-page":"519","volume":"36","author":"A Zabotti","year":"2018","unstructured":"Zabotti, A., Mandl, P., Zampogna, G., Dejaco, C. & Iagnocco, A. One year in review 2018: ultrasonography in rheumatoid arthritis and psoriatic arthritis. Clin. Exp. Rheumatol. 36, 519\u2013525 (2018).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1229_CR61","doi-asserted-by":"publisher","first-page":"438","DOI":"10.11152\/mu-1172","volume":"19","author":"A Zabotti","year":"2017","unstructured":"Zabotti, A. et al. Enthesitis of the hands in psoriatic arthritis: an ultrasonographic perspective. Med. Ultrason. 19, 438\u2013443 (2017).","journal-title":"Med. Ultrason."},{"key":"1229_CR62","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1093\/rheumatology\/kez397","volume":"58","author":"P Mandl","year":"2019","unstructured":"Mandl, P. & Aletaha, D. The role of ultrasound and magnetic resonance imaging for treat to target in rheumatoid arthritis and psoriatic arthritis. Rheumatology 58, 2091\u20132098 (2019).","journal-title":"Rheumatology"},{"key":"1229_CR63","doi-asserted-by":"publisher","first-page":"rkab086","DOI":"10.1093\/rap\/rkab086","volume":"5","author":"SR Dubash","year":"2021","unstructured":"Dubash, S. R. et al. Ultrasound shows swollen joints are the better proxy for synovitis than tender joints in DMARD-na\u00efve early psoriatic arthritis. Rheumatol. Adv. Pract. 5, rkab086 (2021).","journal-title":"Rheumatol. Adv. Pract."},{"key":"1229_CR64","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1136\/annrheumdis-2018-213609","volume":"77","author":"PV Balint","year":"2018","unstructured":"Balint, P. V. et al. Reliability of a consensus-based ultrasound definition and scoring for enthesitis in spondyloarthritis and psoriatic arthritis: an OMERACT US initiative. Ann. Rheum. Dis. 77, 1730\u20131735 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"1229_CR65","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3899\/jrheum.2024-0260","volume":"51","author":"V Chandran","year":"2024","unstructured":"Chandran, V., Liao, W. & de Vlam, K. Biomarkers in psoriasis and psoriatic arthritis: where are we now? J. Rheumatol. 51, 74\u201376 (2024).","journal-title":"J. Rheumatol."},{"key":"1229_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7046","volume":"6","author":"J Bowes","year":"2015","unstructured":"Bowes, J. et al. Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis. Nat. Commun. 6, 6046 (2015).","journal-title":"Nat. Commun."},{"key":"1229_CR67","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.178213","volume":"9","author":"CT Ritchlin","year":"2024","unstructured":"Ritchlin, C. T. et al. Psoriatic arthritis subtypes are phenocopied in humanized mice. JCI Insight 9, e178213 (2024).","journal-title":"JCI Insight"},{"key":"1229_CR68","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1136\/ard-2022-222852","volume":"82","author":"JJ Kuiper","year":"2023","unstructured":"Kuiper, J. J. et al. EULAR study group on \u2018MHC-I-opathy\u2019: identifying disease-overarching mechanisms across disciplines and borders. Ann. Rheum. Dis. 82, 887\u2013896 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"1229_CR69","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3899\/jrheum.190119","volume":"95","author":"DD O\u2019Rielly","year":"2019","unstructured":"O\u2019Rielly, D. D., Jani, M., Rahman, P. & Elder, J. T. The genetics of psoriasis and psoriatic arthritis. J. Rheumatol. Suppl. 95, 46\u201350 (2019).","journal-title":"J. Rheumatol. Suppl."},{"key":"1229_CR70","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1136\/annrheumdis-2016-209275","volume":"75","author":"M Merashli","year":"2016","unstructured":"Merashli, M., De Marco, G., Podgorski, M., McGonagle, D. & Marzo-Ortega, H. Evidence of response to IL-6 inhibition in some cases of refractory spondyloarthritis-associated peripheral synovitis. Ann. Rheum. Dis. 75, 1418\u20131420 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"1229_CR71","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1016\/j.jid.2022.03.013","volume":"142","author":"C Bridgewood","year":"2022","unstructured":"Bridgewood, C. et al. T Helper 2 IL-4\/IL-13 dual blockade with dupilumab is linked to some emergent T helper 17\u2012type diseases, including seronegative arthritis and enthesitis\/enthesopathy, but not to humoral autoimmune diseases. J. Investig. Dermatol. 142, 2660\u20132667 (2022).","journal-title":"J. Investig. Dermatol."},{"key":"1229_CR72","doi-asserted-by":"publisher","first-page":"5006","DOI":"10.3390\/ijms24055006","volume":"24","author":"MS Ciliento","year":"2023","unstructured":"Ciliento, M. S. et al. Evaluation of the synovial effects of biological and targeted synthetic DMARDs in patients with psoriatic arthritis: a systematic literature review and meta-analysis. Int. J. Mol. Sci. 24, 5006 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1229_CR73","doi-asserted-by":"publisher","first-page":"1298583","DOI":"10.3389\/fimmu.2023.1298583","volume":"14","author":"C Garaffoni","year":"2023","unstructured":"Garaffoni, C. et al. High-grade synovitis associates with clinical markers and response to therapy in chronic inflammatory arthritis: post hoc analysis of a synovial biomarkers prospective cohort study. Front. Immunol. 14, 1298583 (2023).","journal-title":"Front. Immunol."},{"key":"1229_CR74","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1080\/03009742.2023.2258644","volume":"53","author":"C Roseman","year":"2024","unstructured":"Roseman, C. et al. Persistent pain and its predictors after starting anti-tumour necrosis factor therapy in psoriatic arthritis: what is the role of inflammation control? Scand. J. Rheumatol. 53, 94\u2013103 (2024).","journal-title":"Scand. J. Rheumatol."},{"key":"1229_CR75","doi-asserted-by":"publisher","unstructured":"Samuel, C. et al. Characteristics associated with patient-reported treatment success in psoriatic arthritis. Rheumatology https:\/\/doi.org\/10.1093\/rheumatology\/keae149 (2024).","DOI":"10.1093\/rheumatology\/keae149"},{"key":"1229_CR76","doi-asserted-by":"publisher","first-page":"101415","DOI":"10.1016\/j.berh.2019.04.007","volume":"33","author":"A-P Trouvin","year":"2019","unstructured":"Trouvin, A.-P. & Perrot, S. New concepts of pain. Best. Pract. Res. Clin. Rheumatol. 33, 101415 (2019).","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"1229_CR77","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1097\/BOR.0000000000001023","volume":"36","author":"PJ Mease","year":"2024","unstructured":"Mease, P. J. Navigating the complexity of pain in psoriatic arthritis and axial spondyloarthritis. Curr. Opin. Rheumatol. 36, 282\u2013288 (2024).","journal-title":"Curr. Opin. Rheumatol."},{"key":"1229_CR78","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1080\/1744666X.2024.2400294","volume":"21","author":"N Horbal","year":"2025","unstructured":"Horbal, N. & Maksymowych, W. P. Nociplastic pain in axial spondyloarthritis and psoriatic arthritis: role of JAK kinases in immunopathology and therapeutic impact of JAK inhibitors. Expert. Rev. Clin. Immunol. 21, 137\u2013152 (2025).","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"1229_CR79","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0180014","volume":"12","author":"S Rifbjerg-Madsen","year":"2017","unstructured":"Rifbjerg-Madsen, S. et al. Pain and pain mechanisms in patients with inflammatory arthritis: a Danish nationwide cross-sectional DANBIO registry survey. PLoS ONE 12, e0180014 (2017).","journal-title":"PLoS ONE"},{"key":"1229_CR80","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1007\/s40744-022-00482-5","volume":"9","author":"K de Vlam","year":"2022","unstructured":"de Vlam, K. et al. Identifying and quantifying the role of inflammation in pain reduction for patients with psoriatic arthritis treated with tofacitinib: a mediation analysis. Rheumatol. Ther. 9, 1451\u20131464 (2022).","journal-title":"Rheumatol. Ther."},{"key":"1229_CR81","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/art.42429","volume":"75","author":"F Sunzini","year":"2023","unstructured":"Sunzini, F., Schrepf, A., Clauw, D. J. & Basu, N. The biology of pain: through the rheumatology lens. Arthritis Rheumatol. 75, 650\u2013660 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"1229_CR82","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1136\/annrheumdis-2016-209511","volume":"76","author":"D Aletaha","year":"2017","unstructured":"Aletaha, D., Alasti, F. & Smolen, J. S. Disease activity states of the DAPSA, a psoriatic arthritis specific instrument, are valid against functional status and structural progression. Ann. Rheum. Dis. 76, 418\u2013421 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"1229_CR83","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/ard.2008.102053","volume":"69","author":"LC Coates","year":"2010","unstructured":"Coates, L. C., Fransen, J. & Helliwell, P. S. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann. Rheum. Dis. 69, 48\u201353 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"1229_CR84","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/art.22531","volume":"57","author":"BF Leeb","year":"2007","unstructured":"Leeb, B. F. et al. The disease activity score in 28 joints in rheumatoid arthritis and psoriatic arthritis patients. Arthritis Rheum. 57, 256\u2013260 (2007).","journal-title":"Arthritis Rheum."},{"key":"1229_CR85","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.3899\/jrheum.160904","volume":"44","author":"A-M Orbai","year":"2017","unstructured":"Orbai, A.-M. et al. Updating the psoriatic arthritis (PsA) core domain set: a report from the PsA workshop at OMERACT 2016. J. Rheumatol. 44, 1522\u20131528 (2017).","journal-title":"J. Rheumatol."},{"key":"1229_CR86","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1001\/jamadermatol.2024.1677","volume":"160","author":"G Hjort","year":"2024","unstructured":"Hjort, G., Schwarz, C. W., Skov, L. & Loft, N. Clinical characteristics associated with response to biologics in the treatment of psoriasis: a meta-analysis. JAMA Dermatol. 160, 830\u2013837 (2024).","journal-title":"JAMA Dermatol."},{"key":"1229_CR87","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec, L. et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann. Rheum. Dis. 79, 700\u2013712 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"1229_CR88","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3899\/jrheum.171411","volume":"46","author":"P Macchioni","year":"2019","unstructured":"Macchioni, P. et al. Ultrasonographic and clinical assessment of peripheral enthesitis in patients with psoriatic arthritis, psoriasis, and fibromyalgia syndrome: the ULISSE study. J. Rheumatol. 46, 904\u2013911 (2019).","journal-title":"J. Rheumatol."},{"key":"1229_CR89","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/acr.25358","volume":"76","author":"P Mease","year":"2024","unstructured":"Mease, P., Reed, G., Ogdie, A., Pappas, D. A. & Kremer, J. M. Prevalence of fibromyalgia and widespread pain in psoriatic arthritis: association with disease severity assessment in a large US registry. Arthritis Care Res 76, 1313\u20131321 (2024).","journal-title":"Arthritis Care Res"},{"key":"1229_CR90","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1136\/annrheumdis-2012-201299","volume":"71","author":"TJ Love","year":"2012","unstructured":"Love, T. J. et al. Obesity and the risk of psoriatic arthritis: a population-based study. Ann. Rheum. Dis. 71, 1273\u20131277 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"1229_CR91","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1111\/bjd.18227","volume":"182","author":"A Green","year":"2020","unstructured":"Green, A. et al. Modifiable risk factors and the development of psoriatic arthritis in people with psoriasis. Br. J. Dermatol. 182, 714\u2013720 (2020).","journal-title":"Br. J. Dermatol."},{"key":"1229_CR92","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1093\/rheumatology\/kew326","volume":"55","author":"P H\u00f8jgaard","year":"2016","unstructured":"H\u00f8jgaard, P. et al. The influence of obesity on response to tumour necrosis factor-\u03b1 inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries. Rheumatology 55, 2191\u20132199 (2016).","journal-title":"Rheumatology"},{"key":"1229_CR93","first-page":"472","volume":"38","author":"A Di Matteo","year":"2020","unstructured":"Di Matteo, A. et al. How normal is the enthesis by ultrasound in healthy subjects? Clin. Exp. Rheumatol. 38, 472\u2013478 (2020).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1229_CR94","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1136\/annrheumdis-2013-203643","volume":"73","author":"P Jacques","year":"2014","unstructured":"Jacques, P. et al. Proof of concept: enthesitis and new bone formation in spondyloarthritis are driven by mechanical strain and stromal cells. Ann. Rheum. Dis. 73, 437\u2013445 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"1229_CR95","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s10067-020-04981-0","volume":"39","author":"R Felten","year":"2020","unstructured":"Felten, R., Duret, P.-M., Gottenberg, J.-E., Spielmann, L. & Messer, L. At the crossroads of gout and psoriatic arthritis: \u2018psout\u2019. Clin. Rheumatol. 39, 1405\u20131413 (2020).","journal-title":"Clin. Rheumatol."},{"key":"1229_CR96","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.semarthrit.2015.11.014","volume":"45","author":"C Petsch","year":"2016","unstructured":"Petsch, C. et al. Prevalence of monosodium urate deposits in a population of rheumatoid arthritis patients with hyperuricemia. Semin. Arthritis Rheum. 45, 663\u2013668 (2016).","journal-title":"Semin. Arthritis Rheum."},{"key":"1229_CR97","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002383","volume":"8","author":"M Krekeler","year":"2022","unstructured":"Krekeler, M., Baraliakos, X., Tsiami, S. & Braun, J. High prevalence of chondrocalcinosis and frequent comorbidity with calcium pyrophosphate deposition disease in patients with seronegative rheumatoid arthritis. RMD Open. 8, e002383 (2022).","journal-title":"RMD Open."},{"key":"1229_CR98","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1080\/1744666X.2021.1825941","volume":"16","author":"E Lubrano","year":"2020","unstructured":"Lubrano, E., Scriffignano, S. & Perrotta, F. M. Multimorbidity and comorbidity in psoriatic arthritis \u2014 a perspective. Expert. Rev. Clin. Immunol. 16, 963\u2013972 (2020).","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"1229_CR99","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002781","volume":"9","author":"A De Vicente Delm\u00e1s","year":"2023","unstructured":"De Vicente Delm\u00e1s, A. et al. Uveitis in psoriatic arthritis: study of 406 patients in a single university center and literature review. RMD Open. 9, e002781 (2023).","journal-title":"RMD Open."},{"key":"1229_CR100","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s40744-024-00709-7","volume":"11","author":"A Zabotti","year":"2024","unstructured":"Zabotti, A. et al. The challenge of IBD-related arthritis screening questionnaires in early and predominantly entheseal phenotypes. Rheumatol. Ther. 11, 1321\u20131331 (2024).","journal-title":"Rheumatol. Ther."},{"key":"1229_CR101","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","volume":"61","author":"W Hueber","year":"2012","unstructured":"Hueber, W. et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61, 1693\u20131700 (2012).","journal-title":"Gut"},{"key":"1229_CR102","first-page":"1131","volume":"12","author":"MJ Fobelo Lozano","year":"2018","unstructured":"Fobelo Lozano, M. J., Serrano Gim\u00e9nez, R. & Castro Fern\u00e1ndez, M. Emergence of inflammatory bowel disease during treatment with secukinumab. J. Crohns Colitis 12, 1131\u20131133 (2018).","journal-title":"J. Crohns Colitis"},{"key":"1229_CR103","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3899\/jrheum.170150","volume":"44","author":"A Ogdie","year":"2017","unstructured":"Ogdie, A. et al. Defining outcome measures for psoriatic arthritis: a report from the GRAPPA-OMERACT working group. J. Rheumatol. 44, 697\u2013700 (2017).","journal-title":"J. Rheumatol."},{"key":"1229_CR104","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1002\/art.42640","volume":"75","author":"G Koduri","year":"2023","unstructured":"Koduri, G. & Solomon, J. J. Identification, monitoring, and management of rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol. 75, 2067\u20132077 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"1229_CR105","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1002\/art.27405","volume":"62","author":"T Bongartz","year":"2010","unstructured":"Bongartz, T. et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum. 62, 1583\u20131591 (2010).","journal-title":"Arthritis Rheum."},{"key":"1229_CR106","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s10067-013-2273-8","volume":"32","author":"M Radic","year":"2013","unstructured":"Radic, M., Martinovic Kaliterna, D. & Radic, J. Overview of vasculitis and vasculopathy in rheumatoid arthritis \u2014 something to think about. Clin. Rheumatol. 32, 937\u2013942 (2013).","journal-title":"Clin. Rheumatol."},{"key":"1229_CR107","doi-asserted-by":"publisher","first-page":"rkae074","DOI":"10.1093\/rap\/rkae074","volume":"8","author":"AL Ribeiro","year":"2024","unstructured":"Ribeiro, A. L. et al. Deciphering difficult-to-treat psoriatic arthritis (D2T-PsA): a GRAPPA perspective from an international survey of healthcare professionals. Rheumatol. Adv. Pract. 8, rkae074 (2024).","journal-title":"Rheumatol. Adv. Pract."},{"key":"1229_CR108","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/rheumatology\/keu328","volume":"54","author":"D McGonagle","year":"2015","unstructured":"McGonagle, D., Hermann, K.-G. A. & Tan, A. L. Differentiation between osteoarthritis and psoriatic arthritis: implications for pathogenesis and treatment in the biologic therapy era. Rheumatology 54, 29\u201338 (2015).","journal-title":"Rheumatology"},{"key":"1229_CR109","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1002\/art.21736","volume":"54","author":"AL Tan","year":"2006","unstructured":"Tan, A. L., Grainger, A. J., Tanner, S. F., Emery, P. & McGonagle, D. A high-resolution magnetic resonance imaging study of distal interphalangeal joint arthropathy in psoriatic arthritis and osteoarthritis: are they the same? Arthritis Rheum. 54, 1328\u20131333 (2006).","journal-title":"Arthritis Rheum."},{"key":"1229_CR110","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1136\/annrheumdis-2017-212662","volume":"77","author":"R Geenen","year":"2018","unstructured":"Geenen, R. et al. EULAR recommendations for the health professional\u2019s approach to pain management in inflammatory arthritis and osteoarthritis. Ann. Rheum. Dis. 77, 797\u2013807 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"1229_CR111","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/ejp.2183","volume":"28","author":"J Vela","year":"2024","unstructured":"Vela, J. et al. Quantitative sensory testing, psychological profiles and clinical pain in patients with psoriatic arthritis and hand osteoarthritis experiencing pain of at least moderate intensity. Eur. J. Pain 28, 310\u2013321 (2024).","journal-title":"Eur. J. Pain"},{"key":"1229_CR112","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/s41584-022-00810-7","volume":"18","author":"S Tarannum","year":"2022","unstructured":"Tarannum, S. et al. Sex- and gender-related differences in psoriatic arthritis. Nat. Rev. Rheumatol. 18, 513\u2013526 (2022).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1229_CR113","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1093\/rheumatology\/key140","volume":"57","author":"P H\u00f8jgaard","year":"2018","unstructured":"H\u00f8jgaard, P. et al. Gender differences in biologic treatment outcomes \u2014 a study of 1750 patients with psoriatic arthritis using Danish Health Care Registers. Rheumatology 57, 1651\u20131660 (2018).","journal-title":"Rheumatology"},{"key":"1229_CR114","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1093\/rheumatology\/kex387","volume":"57","author":"C Stober","year":"2018","unstructured":"Stober, C. et al. Prevalence and predictors of tumour necrosis factor inhibitor persistence in psoriatic arthritis. Rheumatology 57, 158\u2013163 (2018).","journal-title":"Rheumatology"},{"key":"1229_CR115","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1136\/annrheumdis-2012-201357","volume":"72","author":"L Eder","year":"2013","unstructured":"Eder, L., Thavaneswaran, A., Chandran, V. & Gladman, D. D. Gender difference in disease expression, radiographic damage and disability among patients with psoriatic arthritis. Ann. Rheum. Dis. 72, 578\u2013582 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"1229_CR116","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.3899\/jrheum.150165","volume":"42","author":"M Geijer","year":"2015","unstructured":"Geijer, M. et al. The Swedish early psoriatic arthritis registry 5-year followup: substantial radiographic progression mainly in men with high disease activity and development of dactylitis. J. Rheumatol. 42, 2110\u20132117 (2015).","journal-title":"J. Rheumatol."},{"key":"1229_CR117","doi-asserted-by":"publisher","first-page":"7938","DOI":"10.3390\/ijms21217938","volume":"21","author":"J-R Kim","year":"2020","unstructured":"Kim, J.-R. & Kim, H. A. Molecular mechanisms of sex-related differences in arthritis and associated pain. Int. J. Mol. Sci. 21, 7938 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"1229_CR118","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1016\/j.neuron.2021.06.015","volume":"109","author":"X Luo","year":"2021","unstructured":"Luo, X. et al. IL-23\/IL-17A\/TRPV1 axis produces mechanical pain via macrophage-sensory neuron crosstalk in female mice. Neuron 109, 2691\u20132706.e5 (2021).","journal-title":"Neuron"},{"key":"1229_CR119","doi-asserted-by":"publisher","first-page":"1283251","DOI":"10.3389\/fimmu.2023.1283251","volume":"14","author":"C Valero-Mart\u00ednez","year":"2023","unstructured":"Valero-Mart\u00ednez, C. et al. Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain. Front. Immunol. 14, 1283251 (2023).","journal-title":"Front. Immunol."},{"key":"1229_CR120","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3899\/jrheum.110295","volume":"39","author":"R Cuchacovich","year":"2012","unstructured":"Cuchacovich, R., Garcia-Valladares, I. & Espinoza, L. R. Combination biologic treatment of refractory psoriasis and psoriatic arthritis. J. Rheumatol. 39, 187\u2013193 (2012).","journal-title":"J. Rheumatol."},{"key":"1229_CR121","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1136\/annrheumdis-2022-222415","volume":"81","author":"D Simon","year":"2022","unstructured":"Simon, D., Fagni, F. & Schett, G. Sequential interleukin-17\/interleukin-23 inhibition in treatment-refractory psoriatic arthritis. Ann. Rheum. Dis. 81, 1334\u20131336 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"1229_CR122","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1136\/ard-2024-225800","volume":"83","author":"MG Hren","year":"2024","unstructured":"Hren, M. G. & Khattri, S. Treatment of recalcitrant psoriasis and psoriatic arthritis with a combination of a biologic plus an oral JAK or TYK2 inhibitor: a case series. Ann. Rheum. Dis. 83, 1392\u20131393 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"1229_CR123","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S2468-1253(22)00427-7","volume":"8","author":"BG Feagan","year":"2023","unstructured":"Feagan, B. G. et al. Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. Lancet Gastroenterol. Hepatol. 8, 307\u2013320 (2023).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1229_CR124","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1002\/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K","volume":"41","author":"AM van Gestel","year":"1998","unstructured":"van Gestel, A. M., Haagsma, C. J. & van Riel, P. L. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum. 41, 1845\u20131850 (1998).","journal-title":"Arthritis Rheum."},{"key":"1229_CR125","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1136\/ard.2009.117945","volume":"69","author":"VP Nell-Duxneuner","year":"2010","unstructured":"Nell-Duxneuner, V. P. et al. Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis. Ann. Rheum. Dis. 69, 546\u2013549 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"1229_CR126","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1136\/annrheumdis-2012-201341","volume":"72","author":"PS Helliwell","year":"2013","unstructured":"Helliwell, P. S. et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann. Rheum. Dis. 72, 986\u2013991 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"1229_CR127","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1093\/rheumatology\/35.11.1101","volume":"35","author":"ML Prevoo","year":"1996","unstructured":"Prevoo, M. L. et al. Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br. J. Rheumatol. 35, 1101\u20131105 (1996).","journal-title":"Br. J. Rheumatol."},{"key":"1229_CR128","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1136\/ard.2006.051706","volume":"65","author":"J Fransen","year":"2006","unstructured":"Fransen, J. et al. Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. Ann. Rheum. Dis. 65, 1373\u20131378 (2006).","journal-title":"Ann. Rheum. Dis."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-025-01229-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-025-01229-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-025-01229-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T03:54:53Z","timestamp":1743047693000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-025-01229-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":128,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1229"],"URL":"https:\/\/doi.org\/10.1038\/s41584-025-01229-6","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,12]]},"assertion":[{"value":"10 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no competing interests to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}